文献速递白血病

儿童急性髓系白血病的免疫治疗机遇

Opportunities for immunotherapy in childhood acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2019-01-01

本文综述了当前临床评估中的抗体类和细胞免疫治疗,重点介绍针对复发/难治性儿童AML正在或即将开展的1期试验。

要点

  • B-ALL免疫治疗的成功为AML带来希望,但AML存在独特挑战。
  • 综述聚焦复发/难治性儿童AML的抗体和细胞免疫治疗1期试验。

核心结论

  • 儿童AML需要替代化疗的新疗法,免疫治疗是重要方向。
  • AML的生物学和免疫表型异质性及靶抗原在非恶性细胞表达带来的脱靶毒性是独特挑战。

研究设计与样本

  • 综述类文章,检索范围未在摘要中报告。

主要发现

  • 化疗耐药和复发仍是儿童癌症相关死亡的主要来源。
  • B-ALL的体液和细胞免疫治疗在儿童和成人复发/难治患者中取得显著成功。

临床怎么用

  • 综述当前临床评估中的抗体类和细胞免疫治疗,重点关注复发/难治性儿童AML的1期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical outcomes for children with acute myeloid leukemia (AML) have improved minimally during the past 4 decades despite maximally intensive chemotherapy, hematopoietic stem cell transplantation, and optimized supportive care. Chemoresistance and relapse remain major sources of childhood cancer-associated mortality and highlight the need for alternative treatment approaches. The remarkable recent success of humoral and cellular immunotherapies in children and adults with relapsed/refractory B-acute lymphoblastic leukemia has inspired hope for similar accomplishments in patients with AML. However, unique challenges exist, including the biologic and immunophenotypic heterogeneity of childhood AML and the significant potential for on-target/off-tumor immunotherapeutic toxicity due to target antigen expression on nonmalignant cells. This article reviews the current landscape of antibody-based and cellular immunotherapies under current clinical evaluation with an emphasis on active or soon-to-open phase 1 trials for children with relapsed/refractory AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lamble AJ, Tasian SK. Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Adv. 2019. PMID: 31770440. doi:10.1182/bloodadvances.2019000357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。